KR102486064B1 - 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자 - Google Patents

사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자 Download PDF

Info

Publication number
KR102486064B1
KR102486064B1 KR1020217041104A KR20217041104A KR102486064B1 KR 102486064 B1 KR102486064 B1 KR 102486064B1 KR 1020217041104 A KR1020217041104 A KR 1020217041104A KR 20217041104 A KR20217041104 A KR 20217041104A KR 102486064 B1 KR102486064 B1 KR 102486064B1
Authority
KR
South Korea
Prior art keywords
administration
days
binding molecule
pharmaceutical composition
cell antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217041104A
Other languages
English (en)
Korean (ko)
Other versions
KR20220019706A (ko
Inventor
다카히로 이시구로
쇼헤이 기시시타
미키코 나카무라
롤랜드 카네오 몰리
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Priority to KR1020237000158A priority Critical patent/KR20230011470A/ko
Publication of KR20220019706A publication Critical patent/KR20220019706A/ko
Application granted granted Critical
Publication of KR102486064B1 publication Critical patent/KR102486064B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020217041104A 2019-06-10 2020-06-10 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자 Active KR102486064B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237000158A KR20230011470A (ko) 2019-06-10 2020-06-10 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2019-107894 2019-06-10
JP2019107894 2019-06-10
JP2019124364 2019-07-03
JPJP-P-2019-124364 2019-07-03
PCT/JP2020/022771 WO2020250915A1 (ja) 2019-06-10 2020-06-10 サイトカイン阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237000158A Division KR20230011470A (ko) 2019-06-10 2020-06-10 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자

Publications (2)

Publication Number Publication Date
KR20220019706A KR20220019706A (ko) 2022-02-17
KR102486064B1 true KR102486064B1 (ko) 2023-01-06

Family

ID=73780894

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217041104A Active KR102486064B1 (ko) 2019-06-10 2020-06-10 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
KR1020237000158A Pending KR20230011470A (ko) 2019-06-10 2020-06-10 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237000158A Pending KR20230011470A (ko) 2019-06-10 2020-06-10 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자

Country Status (13)

Country Link
US (1) US20220348658A1 (https=)
EP (1) EP3981429A4 (https=)
JP (2) JP7082245B2 (https=)
KR (2) KR102486064B1 (https=)
CN (1) CN114126649A (https=)
AU (1) AU2020291300A1 (https=)
CA (1) CA3140537A1 (https=)
CR (1) CR20220008A (https=)
IL (1) IL288374A (https=)
MA (1) MA56131A (https=)
MX (1) MX2021015007A (https=)
TW (1) TWI868154B (https=)
WO (1) WO2020250915A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
TW202200615A (zh) * 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
CA3214628A1 (en) * 2021-04-06 2022-10-13 Memorial Sloan-Kettering Cancer Center Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
WO2024083959A1 (en) * 2022-10-20 2024-04-25 Monta Biosciences Aps Pre-medication and improved treatment regimen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773719A (en) 1966-12-06 1973-11-20 Hoffmann La Roche 2-aminoxy-2'-acyl-acetanilide
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
AU2015244814B2 (en) 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107556387A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Blood, 2013, Vol. 121(26), pp. 5154-5157
Blood, 2018, Vol. 132(Sup. 1), pp. 1455
Blood, 2018, Vol. 132(Sup. 1), pp. 5211
Blood, 2018, Vol. 132(Sup. 1), pp.1690
Clinical lymphoma, myeloma & leukemia, 2017, Vol. 17(12), pp. 897-901

Also Published As

Publication number Publication date
JPWO2020250915A1 (https=) 2020-12-17
CN114126649A (zh) 2022-03-01
KR20220019706A (ko) 2022-02-17
CR20220008A (es) 2022-02-11
KR20230011470A (ko) 2023-01-20
JP7082245B2 (ja) 2022-06-07
US20220348658A1 (en) 2022-11-03
AU2020291300A1 (en) 2022-01-06
EP3981429A9 (en) 2022-07-06
EP3981429A4 (en) 2023-07-26
MX2021015007A (es) 2022-01-31
TW202112395A (zh) 2021-04-01
EP3981429A1 (en) 2022-04-13
CA3140537A1 (en) 2020-12-17
JP2022116185A (ja) 2022-08-09
IL288374A (en) 2022-01-01
WO2020250915A1 (ja) 2020-12-17
MA56131A (fr) 2022-04-13
TWI868154B (zh) 2025-01-01

Similar Documents

Publication Publication Date Title
JP7242760B2 (ja) ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法
CN110536903B (zh) 抗ox40抗体及其用途
KR102486064B1 (ko) 사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
KR102422411B1 (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
JP2022141693A (ja) インターロイキン２に結合する抗体およびその使用
JP2021088593A (ja) 癌治療のための抗ｆａｍ１９ａ５抗体の用途
KR20170068458A (ko) 항-ｎｋｇ2ａ 항체를 사용한 치료 요법
WO2021028921A9 (en) Antibodies against ilt2 and use thereof
JP2023078311A (ja) 血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子
KR20250039519A (ko) 항-pd-1 항체-약화된 il-2 면역접합체 및 그의 용도
WO2021058735A1 (en) Cancer treatment with anti-met antibody compositions
HK40064168A (en) Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
HK40082394A (en) Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211215

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220609

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20220609

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220802

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221007

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230104

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230104

End annual number: 3

Start annual number: 1

PG1601 Publication of registration